Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive modelEva Hellström‐Lindberg, Peter L. Greenberg, Greger Lindberg et al.|British Journal of Haematology|1997Cited by 314
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceArmon Azizi, Tian Yi Zhang, Asiri Ediriwickrema et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 29